

P

lacing to Raise £5 Million

24 February 2014 – Proteome Sciences plc (“Proteome Sciences” or the “Company”) is pleased to announce that it has conditionally placed 17,857,143 new ordinary shares of 1p each (“New Ordinary Shares”) to raise £5 million before expenses with new and existing investors (the “Placing”) at 28p per share (the “Placing Price”) to provide additional working capital for the Company. Christopher Pearce, Chief Executive of the Proteome Sciences, has subscribed for 3,571,429 New Ordinary Shares in the Placing at the Placing Price. Following this transaction Christopher Pearce will hold 35,109,504 ordinary shares in the Company representing 16.4 per cent. of the Company’s enlarged share capital.

Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that dealings in the New Ordinary Shares will commence trading at 08:00 on or around 28 February 2014 (“Admission”). Following Admission, The New Ordinary Shares will, when issued, rank pari passu in all respects with the existing ordinary shares.

In conformity with rule 5.6.1 of Disclosure and Transparency Rules, the Board of the Company notifies the market of the following:

The total number of ordinary shares of 1p each in Proteome in issue following the admission of the 17,857,143 New Ordinary Shares will be 214,105,620 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Proteome Sciences under the FCA's Disclosure and Transparency Rules.

ENDS
For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer
Dr. Ian Pike, Chief Operating Officer
James Malthouse, Finance Director
Tel: +44 (0)1932 865065

Nomination Adviser
Cenkos
Stephen Keys/Camilla Hume
Tel: +44 (0)20 7397 8900

Public Relations
IKON Associates
Adrian Shaw
Tel: +44 (0)1483 271291

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap® Fusion Tribrid, Orbitrap® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company’s own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer’s disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com